205 related articles for article (PubMed ID: 21915270)
21. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
[TBL] [Abstract][Full Text] [Related]
22. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
23. Planning for the next influenza H1N1 season: a modelling study.
Carrat F; Pelat C; Levy-Bruhl D; Bonmarin I; Lapidus N
BMC Infect Dis; 2010 Oct; 10():301. PubMed ID: 20964814
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
Uphoff H; An der Heiden M; Schweiger B; Campe H; Beier D; Helmeke C; Littmann M; Haas W; Buda S; Faensen D; Feig M; Altmann D; Wichmann O; Eckmanns T; Buchholz U
PLoS One; 2011; 6(7):e19932. PubMed ID: 21789163
[TBL] [Abstract][Full Text] [Related]
25. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
[TBL] [Abstract][Full Text] [Related]
26. Pre- and post-pandemic prevalence of antibodies to the 2009 pandemic influenza A (H1N1) virus in Austrian adults.
Poeppl W; Poeppl G; Hunger M; Tobudic S; Winkler H; Faas A; Mooseder G; Burgmann H
J Med Virol; 2012 Sep; 84(9):1331-4. PubMed ID: 22825809
[TBL] [Abstract][Full Text] [Related]
27. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
[TBL] [Abstract][Full Text] [Related]
28. Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.
Ito H; Nishimura H; Kisu T; Hagiwara H; Watanabe O; Kadji FMN; Sato K; Omiya S; Takashita E; Nobusawa E
PLoS One; 2020; 15(5):e0233001. PubMed ID: 32401814
[TBL] [Abstract][Full Text] [Related]
29. Infection with influenza A(H1N1)pdm09 during the first wave of the 2009 pandemic: Evidence from a longitudinal seroepidemiologic study in Dhaka, Bangladesh.
Nasreen S; Rahman M; Hancock K; Katz JM; Goswami D; Sturm-Ramirez K; Holiday C; Jefferson S; Branch A; Wang D; Veguilla V; Widdowson MA; Fry AM; Brooks WA
Influenza Other Respir Viruses; 2017 Sep; 11(5):394-398. PubMed ID: 28688210
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine.
Zhou Y; Ng DM; Seto WH; Ip DK; Kwok HK; Ma ES; Ng S; Lau LL; Peiris JS; Cowling BJ
PLoS One; 2011; 6(11):e27169. PubMed ID: 22102878
[TBL] [Abstract][Full Text] [Related]
31. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
33. Association between Hemagglutinin Stem-Reactive Antibodies and Influenza A/H1N1 Virus Infection during the 2009 Pandemic.
Hoa LNM; Mai LQ; Bryant JE; Thai PQ; Hang NLK; Yen NTT; Duong TN; Thoang DD; Horby P; Werheim HFL; Fox A
J Virol; 2016 Jul; 90(14):6549-6556. PubMed ID: 27170747
[TBL] [Abstract][Full Text] [Related]
34. Immune response to 2009 pandemic H1N1 influenza virus A monovalent vaccine in children with cancer.
Yen TY; Jou ST; Yang YL; Chang HH; Lu MY; Lin DT; Lin KH; Huang LM; Chang LY
Pediatr Blood Cancer; 2011 Dec; 57(7):1154-8. PubMed ID: 21425448
[TBL] [Abstract][Full Text] [Related]
35. Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine.
Sun Y; Bian C; Xu K; Hu W; Wang T; Cui J; Wu H; Ling Z; Ji Y; Lin G; Tian L; Zhou Y; Li B; Hu G; Yu N; An W; Pan R; Zhou P; Leng Q; Huang Z; Ma X; Sun B
PLoS One; 2010 Dec; 5(12):e14270. PubMed ID: 21151563
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA
Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860
[TBL] [Abstract][Full Text] [Related]
37. Seroprevalence of influenza A H1N1 and seroconversion of mothers and infants induced by a single dose of monovalent vaccine.
Chao A; Huang YC; Chang YL; Wang TH; Chang SD; Wu TS; Wu TL; Chao AS
Taiwan J Obstet Gynecol; 2013 Sep; 52(3):356-9. PubMed ID: 24075373
[TBL] [Abstract][Full Text] [Related]
38. Seroprevalence of seasonal and pandemic influenza a in Kuala Lumpur, Malaysia in 2008-2010.
Sam IC; Shaw R; Chan YF; Hooi PS; Hurt AC; Barr IG
J Med Virol; 2013 Aug; 85(8):1420-5. PubMed ID: 23765779
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
[TBL] [Abstract][Full Text] [Related]
40. "Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?".
Allwinn R; Bickel M; Lassmann C; Wicker S; Friedrichs I
Med Microbiol Immunol; 2013 Apr; 202(2):125-30. PubMed ID: 22986732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
